We have characterized the fusogenic activity of a plasmid expression system encoding vesicular stomatitis virus G protein ( VSVG ) in vitro and in vivo. Over 70% of murine colon and renal carcinoma cells ( MC38 and Renca, respectively ) transfected with VSVG plasmid in vitro fused and formed polykaryons upon incubation with pH 5.5 media. Using a plasmid expression system encoding VSVG and bacterial green fluorescent protein ( GFP ) formulated in a polyvinyl pyrrolidone ( PVP ) delivery system, diffusion of GFP throughout the VSVG -induced syncytia was shown in vivo in MC38 and Renca tumors. Moreover, tumor -bearing mice showed tumor growth inhibition following in vivo transfection with VSVG plasmid at an optimal dose of 48 g. We have previously shown that direct injection of interleukin -12 ( IL -12 ) plasmid complexed with PVP into tumors induces a strong immune response. In the current study, we assessed the ability of VSVG to elicit an antitumor response by enhancing cytokine gene delivery within the tumor mass. Tumor -bearing mice treated intratumorally with both VSVG / PVP and IL -12 / PVP ( 48 and 24 g, respectively ) showed increase in tumor rejection when compared to IL -12 plasmid alone ( 75% vs. 50%, respectively ) . These data suggest that VSVG gene therapy can be used in combination with other therapeutic genes to induce an antitumor response in vivo by enhancing the expression of the gene of interest. Cancer Gene Therapy ( 2001 ) 2 The VSV glycoprotein ( VSVG ) is a single -polypeptide 55 -kDa envelope glycoprotein that is held in the viral membrane by a domain of hydrophobic amino acids near the carboxyl terminus. More than 95% of each protein molecule is exposed on the surface of the virion.
V esicular stomatitis virus (VSV ) belongs to the Rhabdovirus family of enveloped, negative strand RNA viruses, which enters the host cell through receptormediated endocytosis. 2 The VSV glycoprotein ( VSVG ) is a single -polypeptide 55 -kDa envelope glycoprotein that is held in the viral membrane by a domain of hydrophobic amino acids near the carboxyl terminus. More than 95% of each protein molecule is exposed on the surface of the virion. 3 VSVG is believed to be responsible both for binding of virus to the cell surface and for fusion of the viral envelope with the endosomal membrane after endocytosis. 4 ± 7 This leads to the release of viral nucleocapsid into the cytoplasm of the cell and subsequent infectivity of the virus. Therefore, syncytia formation allows for efficient and rapid cell -to -cell spread of viruses and avoids immune recognition. Like Myxovirus and Togavirus family, Rhabdoviruses are pHdependent for their ability to promote fusion. The pH dependence of virus fusion is a property of the viral fusion protein. Because wild -type VSV is only capable of fusion within low-pH endosomes, it is believed that VSVG protein undergoes a pH -dependent conformational change that is essential for catalyzing the fusion of the viral envelope with the endosomal or cell membranes. 8 The regions of VSVG protein involved in the proposed conformational changes and membrane fusion events have been postulated based on site -directed mutagenesis of specific amino acids in VSVG protein and comparison of the resulting fusogenic activity for mutated and wild -type VSVG. It is hypothesized that the region between amino acids 118 and 139 is important for the membrane fusion activity of VSVG protein and may constitute an internal fusion domain. 9 ± 11 Our approach takes advantage of the highly efficient mechanism of VSVG protein to form syncytia without accompanying harmful viral proteins, such as VSV matrix (M ) protein. 12 There have been many reports demonstrating pH -dependent fusogenic activity of VSVG in a number of mammalian cells in vitro. 13 ± 15 However, little is known about the fusogenic activity of VSVG in vivo. We tested VSVG activity in vivo by direct injection of VSVG ± GFP plasmid formulated in polyvinyl pyrrolidone ( PVP ) into subcutaneous murine renal and colon carcinoma tumors ( Renca and MC38, respectively ).
One of the major obstacles in effective tumor therapy has been limited distribution of therapeutic genes in tumor cells following direct injection. Taking advantage of the fusogenic activity of VSVG to spread therapeutic genes to a larger population of tumor cells is, therefore, an attractive strategy. Cytokine gene therapy has been extensively used for the treatment of cancer. Interleukin -12 (IL -12) has been shown to successfully induce tumor regression and antitumor immunity in experimental models due to its capacity to selectively augment helper T-cell type 1 (Th1 ) responses and its stimulatory effect on natural killer (NK ) cells, thus triggering both specific and nonspecific antitumor cytotoxic responses. 16 We have previously shown that intratumoral administration of IL-12 plasmid ± based delivery induced tumor growth inhibition and elicited a long -term immunity in both renal and colon cell carcinomas. 1 In this study, we present evidence that simultaneous injection of VSVG and IL -12 plasmids formulated in PVP into subcutaneous murine tumors results in increased tumor rejection when compared to treatment with IL -12 alone.
MATERIALS AND METHODS

Plasmid construction and formulation
Plasmid constructs used in this paper all had the same basic backbone and transcription units. Each transcription unit was driven by the human cytomegalovirus (CMV ) immediate early enhancer /promoter, contained a synthetic intron in its 5
H untranslated region and had its 3 H end defined by the human growth hormone poly ( A ) signal. Those plasmids containing two genes had two complete sets of transcription units. VSVG plasmid was constructed by directly amplifying the coding sequence of VSVG (Genbank X03633 ) from the Indiana strain of VSV genomic DNA by polymerase chain reaction ( PCR ) . The PCR product was then cloned into an intermediate plasmid backbone (pCR2.1, Invitrogen, Carlsband, CA ) , and sequence fidelity was verified by DNA sequence analysis for three clones ( data not shown ). The coding sequence for VSVG was then subcloned as an NcoI± XbaI fragment into our expression plasmid ( described earlier ) to create the VSVG expression system pVG1060. Enhanced green fluorescent protein (EGFP ) coding sequence, optimized for brighter fluorescence and higher expression in mammalian cells, was excised from pGF0932 ( Clontech, Palo Alto, CA ) by a NcoI±XbaI digest and subcloned into our expression backbone to create pGF1032. Subsequently, incorporating GFP sequence and its transcription unit into pVG1060 plasmid generated VSVG ± GFP plasmid (pGG1134) . The expression plasmid for mouse IL -12 (pIN0961 ) has been described previously. 17 Briefly, the p35 and p40 subunits of IL -12 are expressed from two independent transcription units that were incorporated into a single plasmid.
1 pVC1157 ( empty plasmid, EP ) was used as a control plasmid in all in vivo experiments; this plasmid contains all the regulatory elements, but lacks a coding sequence. Plasmids for intratumoral injection were grown under kanamycin selection in Escherichia coli host strain DH5 and purified using alkaline lysis and chromatographic methods. Purified plasmids utilized for intratumoral injections had the following specifications: < 50 EU / mg endotoxin, < 20 mOsm /kg osmolality, and !80% active form of plasmid ( supercoiled +open circle ). Purified pVG1060, pGF1032, pGG1134, pIN0961, and pVC1157 plasmids were formulated with 5% PVP in saline as described previously. 18 
Tumor cell lines
Renca, a spontaneously arising murine renal cell carcinoma and MC38, a murine colon cell carcinoma were generously provided by Dr. Drew M. Pardoll (John Hopkins Hospital, Baltimore, MD ) and Dr. Mike Lotze ( University of Pittsburgh, PA ), respectively. Tumor cell cultures were maintained in sterile disposable flasks from Corning ( Corning, NY ) at 378C in a humidified 5% CO 2 atmosphere, using RPMI 1640 supplemented with 10% fetal bovine serum, 100 U / mL penicillin, 100 U /mL streptomycin, and 2 mM L -glutamine ( all from Life Technologies, Gaithersburg, MD ) .
Western blot analysis of VSVG
Renca cells were plated in six -well plates at 3Â10 5 cells / well, and transfected 24 hours later, using 2 g of VSVG plasmid and 12 g of Lipofectamine ( Life Technologies ) in serum -free /antibiotic -free (SF ) RPMI media. SF media was replaced with supplemented RPMI media after 5 hours. Twenty -four hours later, Renca cells were washed twice with phosphate -buffered saline ( Life Technologies ) and lysed with 200 L of lysis buffer ( 50 mM Tris ±HCL pH 7.5, 150 mM NaCl, 0.1% Triton X -100, and 2 L 100Â protease inhibitor ). Lysate was transferred to a microfuge tube and spun for 2 minutes to fractionate soluble and insoluble ( membrane -bound ) fractions. VSVG protein was immunoprecipitated from the soluble fraction using anti -VSVG monoclonal antibody ( Boehringer Mannheim, Indianapolis, IN ) and protein A and G agarose (Boehringer Mannheim ) . Samples were analyzed on a 10% Tris ± glycine gel and electroblotted to Millipore PVDF membrane. Anti -VSVG monoclonal antibody (Boehringer Mannheim ) was used at 1:1000, followed by antisheep Ig-horseradish peroxidase ( HRP, Boehringer Mannheim ) at 1:1000. Biotinylated molecular weight markers were detected using streptavidin ±HRP ( Amersham, Arlington Heights, IL ) . Detection was performed using an ECL kit from Amersham.
Syncytium formation assays
Renca and MC38 cells were plated in six -well plates at 3Â10 5 cells/well, and transfected as described in the Western blot section. At 18 hours posttransfection, cells were rinsed once with fusion media [10 mM Na 2 HPO 4 , 10 mM NaH 2 PO 4 , 150 mM NaCl, 10 mM 2-( N -morpholino ) ethanesulfonic acid ( MES ), 10 mM N -2-hydroxyethylpiperazine -N H -2 -ethanesulfonic acid ( HEPES ); titrated to pH =5.5 with HCl ]. Whereas Renca cells were incubated for 1 minute at 378C with the fusion media, MC38 cells were incubated for only 30 seconds at room temperature ( RT ) because they were very sensitive to fusion media treatment. Subsequently, the fusion medium was replaced with supplemented RPMI media and the plate was returned to a 378C, 5% CO 2 incubator for 45± 60 minutes. Following the incubation at 378C, the medium was removed and ice -cold phosphate -buffered saline containing 0.9 mM CaCl 2 and 0.5 mM MgCl 2 was added. Cultures were maintained at 48C to prevent further cell ±cell fusion until they could be examined for syncytium formation by an inverted light microscope ( Zeiss, Thornwood, NY ) with phase -contrast optics and connections to a camera. The number of single (unfused ) cells and the number of fused cells ( cells with three or more nuclei ) were counted in three to five separate microscopic fields. The percentage of fused cells was determined by first subtracting the background (the number of fused cells in the mock -transfected cultures ) from the experimental groups and then dividing the number of fused cells by the total number of cells and multiplying by 100.
Animals
Six -to eight -week -old female BALB / c mice ( Charles River Laboratories, Wilmington, MA ) and 5 -to 7 -weekold female C57BL /6 mice (Charles River Laboratories ) were maintained on ad libitum rodent feed and water at 238C, humidity 40%, and a 12 hour /12 hour light± dark cycle. Animals were acclimated for at least 7 days before the start of the study. All animal procedures conformed to approved animal use protocols.
Tumor implantation and treatment
To generate tumors, BALB /c or C57BL /6 mice were implanted subcutaneously ( s.c. ) in the middle of the left flank with 30 L of a single -cell suspension containing 7Â10 5 Renca cells or 4Â10 5 MC38 cells, respectively. Tumor volume was measured with an electronic caliper by measuring its two perpendicular diameters and its depth. Treatment of the tumors was started after 7 days when they reached a size of 8 ± 10 mm 3 . Tumors were treated with different plasmid formulations in volumes of 50 L each, at 2 -day intervals for a total of four treatments in 2 weeks. Tumor sizes were measured twice a week for a period of 40 ± 50 days. All mice that developed tumors larger than 1 cm 3 were sacrificed for humane reasons.
Tumor harvest and fluorescent microscopy
Mice bearing Renca or MC38 s.c. tumors approximately 8 ±10 mm 3 in size were treated intratumorally with 48 g of GFP /PVP or GFP -VSVG /PVP formulations. Eighteen hours posttreatment, mice were euthanized and tumors were harvested, fixed in 10% neutral buffered formalin for 6 ±8 hours, and processed to paraffin. Three -micrometer paraffin sections were made, hydrated to water, and coverslipped with Vectashield with or without DAPI ( Vector Laboratories, Burlingame, CA ). The sections were examined with an Olympus BX -60 fluorescent microscope with a SPOT camera (Diagnostic Instruments, Sterling Heights, MI ).
Tumor pH measurement
Tumor pH versus thigh muscle pH was measured in tumorbearing mice ( Renca and MC38 ). BALB /c and C57BL / 6 mice were injected s.c. with 7Â10 5 Renca and 3Â10 5 MC38 cells, respectively, and tumors were allowed to grow to approximately 10 mm 3 . Mice were anesthetized intraperitoneally with 30 L of a combination of Ketamine at 73.96 mg / mL, Xylaxine at 3.74 mg /mL, and Acepromazine at 0.73 mg / mL. An MI -419 Micro pH Electrode with 18 -gauge needle ( Microelectrodes, Bedford, NH ) was then used to measure tumor and muscle pH. The needle probe was vertically inserted approximately half a centimeter into either the tumor mass or the belly of the quadriceps muscle group. It took 10± 15 minutes for each pH reading to equilibrate. All mice that developed tumors larger than 1 cm 3 were sacrificed for humane reasons.
RESULTS
VSVG expression and fusogenic activity in vitro
VSVG protein expression in Renca cells was detected using a Western blot analysis. Renca cells were either left untreated, transfected with EP, or transfected with VSVG expression plasmid ( pVG1060 ) and then treated with a lysis buffer to release the membrane -bound glycoprotein. The resultant soluble and insoluble (still membrane -bound ) fractions from untreated, mock, and VSVG transfected cells were then assayed for VSVG protein expression. The results presented in Figure 1 show that the recombinant VSVG protein expressed from pVG1060 template is present as a single band with an approximate molecular mass of 55 kDa. This band was present in both the soluble and insoluble fractions from cells transfected with VSVG plasmid, but was not observed in cell lysates from cells transfected with empty plasmid or untreated cells.
The cloned VSVG protein was analyzed for low -pH ± dependent fusion activity in a cell ± cell fusion assay. Renca or MC38 cells transfected with EP or VSVG expression plasmid ( pVG1060 ) were treated with the pH 5.5 fusion medium at 378C for 1 minute, or at RT for 30 seconds, respectively. Polykaryons formed after 45± 60 minutes of incubation at 378C were viewed under a phase -contrast microscope (Fig 2 ) . Renca ( upper panels ) and MC38 (lower panels ) transfected with VSVG showed extensive polykaryon formation, and the When left at 378C for several hours, polykaryons rapidly extended to cover the majority of the plate surface area (data Figure 3 . Diffusion of GFP protein in VSVG -induced syncytia. Renca cells were transfected with VSVG ± GFP ( panels A ± C ) or GFP ( panels D ± F ) plasmids and exposed to fusion media at pH 5.5 for 60 seconds. Cells were counterstained with DAPI ( blue ) to show nuclei and photographed with blue filter ( panels A and D ) . The same cells were visualized using green filter ( GFP ) to detect GFP expression and distribution ( panels B and E ) . Photographs shown in panels C and F are taken transposing the blue filter images ( nuclei ) and the green filter images ( GFP ) . Panel C shows syncytia formation with multiple nuclei. not shown ). In all cases, no fusion was observed in the absence of fusion media treatment.
Intercellular diffusion of GFP in VSVG -induced syncytia in vitro and in vivo
Renca cells were transfected with VSVG ± GFP or GFP plasmid and treated with pH 5.5 fusion medium ( Fig 3 ) . The transposed images of cells that are stained for nuclei (blue ) and express GFP ( green ) show that cells transfected with VSVG ±GFP form extensive syncytia carrying multiple nuclei ( Fig 3 panel C ) . On the contrary, cells transfected with GFP alone did not form syncytia because individual cells retaining green fluorescent protein are evident (Fig 3  panel F) . The results presented in Figure 3 illustrate the extent of dispersion of GFP and suggest that a similar distribution pattern could be achieved for other therapeutic proteins when coexpressed with VSVG. The fusogenic activity of VSVG ± GFP plasmid was then tested within the tumor following VSVG ± GFP /PVP treatment. BALB /c mice were challenged s.c. with 7Â10 5 Renca cells or 4Â10 5 MC38 cells and a single injection of VSVG ± GFP / PVP (48 g/ mouse ), GFP /PVP ( 48 g /mouse) , or EP / PVP ( 48 g /mouse) was performed 7 days later when tumors reached approximately 15 mm 3 in size. Tumors were harvested 18 hours postinjection and paraffin sections were made for examination by fluorescent microscopy. The arrows in Figure 4 ( Renca, panels A and B; MC38, panels C and D ) represent multinucleated polykaryon formation by VSVG expression in tumor cells. In tumor sections prepared from tumors injected with GFP /PVP (panels A and C ), GFP expression was present, but was limited to small loci of one Tumor pH versus thigh muscle pH was measured in Balb /c and C57BL / 6 mice. BALB /c and C57BL /6 mice bearing Renca and MC38 tumors, respectively, were anesthetized intraperitoneally. A pH probe with 18 -gauge needle (Microelectrodes ) was then used to measure tumor pH by inserting the probe in either the tumor or muscle tissue and waiting up to 15 minutes for the pH reading to equilibrate. Results in Figure 5 show pH measurements for Renca and MC38 tumors; pH values range from 6.48 to 6.94 in tumor tissue to 7.01 to 7.51 in normal tissue with MC38 tumors having slightly lower pH values than Renca tumors.
Effect of VSVG / PVP treatment on tumor growth inhibition
To determine the optimal VSVG dose that produces maximum syncytia in tumors and tumor growth inhibition, a dose ± response experiment was performed. BALB / c mice were challenged s.c. with 7Â10 5 Renca cells and plasmid injections were initiated 7 days later when tumors reached approximately 10 mm 3 size. Each group of mice received eight treatments at intervals of 1± 2 days (four injections per week ) of VSVG /PVP or VSVG ±GFP /PVP at scalar doses ( from 6 to 96:g/ mouse ), EP /PVP (96:g/mouse ) or no treatment as a control ( ctrl ) . There was statistically significant ( P <.05 ) reduction in tumor growth in the 24, 48, and 96:g dose group, when compared to the untreated group (0:g ) (Fig 6 ) . This plasmid dose also corresponded to maximal syncytia formation in tumors when tumor sections were examined via fluorescent microscopy ( data not shown ).
Antitumor activity of IL -12 and VSVG gene therapy
The antitumor effect of IL-12 and VSVG plasmid each complexed with PVP was tested in the Renca tumor model. Optimal dose of IL -12/ PVP ( 24 g) to achieve an antitumor response in vivo was previously determined using Renca and CT26 ( colon carcinoma ) models. 1 In these studies, BALB / c mice were challenged s.c. with ( Fig 7) . Accordingly, tumor rejection mediated by the IL-12 /PVP + VSVG / PVP treatment was higher (12 of 16 ) than the sum of rejection obtained by IL -12 /PVP ( 8 of 16) and VSVG / PVP alone (1 of 16 ) (Fig 7 ) . Mice that rejected tumors remained tumor-free for as long as they were under observation (40 ± 50 days ). No tumor rejection was observed in the control group and there was only one tumor rejection in the VSVG /PVP group; however, tumor growth inhibition was evident in mice treated only with VSVG /PVP, confirming the results shown in Figure 6 . Thus, VSVG enhanced the antitumor activity of IL -12 gene therapy suggesting an increased efficiency of tumor transfection.
DISCUSSION
In this study, we present evidence that transfection of VSVG plasmid into renal and colon cell carcinoma induces cell fusion in vitro and in vivo. Tumor syncytia formation in vivo was associated with diffusion of GFP expression throughout the syncytia following intratumoral administration of VSVG +GFP /PVP. Tumor-bearing mice treated with VSVG /PVP combined with IL -12 /PVP exhibited a 75% tumor-rejection rate, whereas a 50% tumor rejection was observed in mice treated only with IL -12/ PVP (Fig 7) . These data suggest a cancer treatment using genetically engineered expression vectors that combine VSVG and the target gene to enhance intratumoral delivery.
A Western blot was utilized to confirm protein expression from the VSVG construct. Wild -type G protein contains two N -glycosylation sites, 10 which is evident by the slower migration of the 55-kDa VSVG protein closer to the 69 -kDa marker band (Fig 1) .
When cells were fused in vitro following VSVG treatment, cell detachment, rounding, and eventually death occurred at 24± 48 hours posttreatment. We investigated whether this cell death was due to an apoptotic mechanism by testing for the existence of phosphatidyl serine, a typical early marker of apoptotic process, on the cell surface. We also analyzed DNA that was isolated from transfected cells at 48 hours posttransfection. We were unable to detect phosphatidyl serine presence with Annexin V-FITC staining followed by FACS analysis, nor any laddering pattern of DNA, which is a late hallmark for apoptosis (data not shown) . It is likely that cell death is a result of massive necrosis, rather than apoptosis, due to the loss of homeostatic conditions and major modifications of cell physiology. Our in vivo data also showed some inhibitory effects on tumor growth when tumors were treated with VSVG alone. At 24 -, 48 -, and 96-g doses of VSVG, there was significant tumor reduction when compared to the untreated group.
Based on the relatively small transfection efficiency observed in tumors after direct injection of plasmids, one potential VSVG gene therapy strategy is to use the pHdependent fusogenic capability of coexpressed VSVG in tumors. The combination therapy will enhance the intratumoral delivery and dispersion of secreted and nonsecreted therapeutic genes, their transcribed mRNA, and /or expressed protein to a larger population of tumor cells. Potential candidates include, but are not limited to, cytokine, tumor suppressor, and suicide genes. In our experiments, GFP was initially used as a substitute for therapeutic proteins to demonstrate this strategy. GFP produces a bright green fluorescent protein, which is readily detectable in tumor sections via fluorescent microscopy ( Fig 4) . This strategy takes advantage of the slightly acidic intratumoral environment, which is consistently lower than that of normal tissue by up to 0.9 pH units (Fig 5 ) . It is likely that the pH difference between normal and tumor cells is even more prominent in their microenvironment due to an increase in metabolic activities and waste production associated with tumor growth. However, measurement of this sort was beyond the sensitivity range of our pH meter. Others have also reported that both pH and pO 2 decrease as one moves away from tumor vessels leading to acidic and hypoxic regions in tumors. 19 Although low pH is detrimental to radiation therapy, it might enhance the effect of certain drugs, if the drug could be delivered in adequate quantities to those regions. 20, 21 Introduction of immunostimulatory cytokines is a valuable strategy for generating immune responses against cancer. However, systemic delivery of cytokines for the treatment of cancer in mice and humans is associated with toxic side effects. 22, 23 This limitation created a need for alternative approaches, such as the delivery of cytokine genes to the site of the tumor, 24, 25 that reduce toxicity whereas maintaining the benefits.
Local presence of cytokines in tumors can activate an immune response that, in some cases, leads to induction of long -lasting tumor-specific immunity. IL -12 has proven to be one of the most potent of these cytokines. 1 By direct intratumoral injection of plasmid encoding murine IL -12 in a PINC delivery system, tumor-bearing mice develop an immune response, which leads to inhibition of tumor growth. We have shown previously by performing depletion studies in vivo that the immune response induced by IL-12 is primarily mediated by CD8 + T cells and that this therapy results in a long -term immunity in mice demonstrating complete tumor regression. 1 We have employed a nonviral gene therapy approach to deliver VSVG, GFP, and IL -12 plasmids to the tumor. This approach utilizes an interactive polymeric gene delivery system (PVP ) that increases protein expression by protecting the plasmid (pDNA ) from nucleases and controlling the dispersion and retention of pDNA in injected tissues. 18 These polymeric systems routinely result in higher levels of gene expression from solid tissues compared to delivery of plasmid in saline. 1, 26 The use of VSVG plasmid in combination with a cytokine plasmid, such as IL -12, enhances the surface area of the cytokine secretion due to tumor cell fusion. The size of ESLAHI ET AL: VSVG-ENHANCED IL-12 GENE THERAPY syncytia in Figure 4 ( panels B and D ) indicates that the resultant multinucleated cells are comprised of both cells expressing GFP and the nonexpressers, which would otherwise appear as black regions. Paracrine secretion of IL -12 takes place primarily at the tumor site where the flow of body fluids neither dilutes nor inactivates cytokines quickly. However, the efficiency of IL -12 message decreases owing to its inhibition and dilution as the cell ± cell distance increases.
In this article we demonstrate that coexpression of VSVG and IL-12 enhances the antitumoral effects associated with IL -12 gene therapy. This is accomplished by lessening one of the major shortcomings of intratumoral gene delivery, which is limited transfection of tumor cells. Also, the subsequent cell death and necrosis should create an optimal environment for professional antigen processing cells to uptake fragments of tumors and present their antigens to tumor-specific T lymphocytes, thus enhancing tumor cell recognition.
